Early information from a medical research study suggest that an off-label cancer drug provided clinical benefit to a small group of patients with extreme COVID-19
The cancer drug acalabrutinib, which blocks the Bruton tyrosine kinase (BTK) protein and is approved to treat some blood cancers, was connected with lowered respiratory distress and a reduction in the overactive immune reaction in most of the cured patients, according to the study released Friday in Science Immunology
Researchers caution that the findings should not be thought about scientific guidance however that they are being shared to help with the general public health action to the coronavirus pandemic.
BTK inhibitors are not authorized for treatment of COVID-19; their capacity needs to be tested in a randomized, managed scientific trial, researchers said.
KAWASAKI-LIKE SYNDROME LINKED TO COVID-19 IN CHILDREN IS NEW CONDITION, RESEARCH STUDY EXPOSES
A new research study exposes an off-lab